Advertisement

Advances in Therapy

, Volume 28, Issue 1, pp 13–27 | Cite as

Pitavastatin: a New 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor for the treatment of hyperlipidemia

  • William L. Baker
  • Rupangi Datta
Review

Abstract

Statins have proven beneficial for reducing both primary and secondary events in patients with coronary heart disease. Tight control of serum lipid parameters in these patients is recommended by the most recent clinical guidelines. Although numerous lipid-lowering treatments are available, only a small percentage of eligible patients receive therapy and fewer achieve their lipid-lowering goals. Thus it is clear that new treatment strategies to manage patients with lipid abnormalities are warranted. Pitavastatin (Lival®; Kowa Pharmaceuticals America, Montgomery, AL, USA) has been recently approved for the treatment of hypercholesterolemia and combined dyslipidemia. Pitavastatin 1–4 mg/day has shown similar low-density lipoprotein-reducing activity to other commercially available statins, including simvastatin and atorvastatin. Adverse events occurred at similar rates to other statins in clinical trials with favorable effects seen in patients with dyslipidemia and metabolic syndrome. Pharmacokinetic drug-drug interactions are minimized due to the lack of significant metabolism of pitavastatin by the cytochrome P450 enzyme system, although some drugs affect its uptake into hepatocytes and should be avoided. In addition to its higher acquisition cost, pitavastatin has not been shown to improve clinical outcomes in high-risk patient populations and thus may not be the agent of choice in many patients at this time in lieu of cheaper, clinically proven alternatives.

Keywords

HMG-CoA reductase inhibitor hypercholesterolemia hyperlipidemia pitavastatin statin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy. A meta-analysis of randomized controlled trials. Arch Intern Med. 2006;166:2307–2313.PubMedCrossRefGoogle Scholar
  2. 2.
    Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvaastatin Survival Study (4S). Lancet. 1994;344:1383–1389.Google Scholar
  3. 3.
    Shepherd J, Blauw G, Murphy M, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet. 2002;360:1623–1630.PubMedCrossRefGoogle Scholar
  4. 4.
    Mills EJ, Rachlis B, Wu P, et al. Primary prevention of cardiovascular mortality and events with statin treatments. A network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol. 2008;52:1769–1781.PubMedCrossRefGoogle Scholar
  5. 5.
    Pedersen TR, Facrgeman O, Kastelein JJP, et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction. The IDEAL study: a randomized controlled trial. JAMA. 2005;294:2437–2445.PubMedCrossRefGoogle Scholar
  6. 6.
    Cannon CP, Braunwald D, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350:1495–1504.PubMedCrossRefGoogle Scholar
  7. 7.
    Josan K, Majumdar SR, McAlister FA. The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008;178:576–584.PubMedCrossRefGoogle Scholar
  8. 8.
    Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267–1278.CrossRefGoogle Scholar
  9. 9.
    Robinson JG, Wang S, Smith BJ, Jacobson TA. Meta-analysis of the relationship between nonhigh-density lipoprotein cholesterol reduction and coronary heart disease risk. J Am Coll Cardiol. 2009;53:316–322.PubMedCrossRefGoogle Scholar
  10. 10.
    National Cholesterol Education Panel. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. Circulation. 2002;106:3143–3421.Google Scholar
  11. 11.
    Grundy SM, Cleeman JI, Merz CNB, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227–239.PubMedCrossRefGoogle Scholar
  12. 12.
    Brunzell JD, Davidson M, Furberg CD, et al. Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol. 2008;51:1512–1524.PubMedCrossRefGoogle Scholar
  13. 13.
    Armitage J. The safety of statins in clinical practice. Lancet. 2007;370:1781–1790.PubMedCrossRefGoogle Scholar
  14. 14.
    Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009;150:858–868.PubMedGoogle Scholar
  15. 15.
    Kotseva K, Stagmo M, De Bacquer D, et al. Treatment potential for cholesterol management in patients with heart disease in 15 European countries: findings from the EUROASPIRE II survey. Atherosclerosis. 2008;197:710–717.PubMedCrossRefGoogle Scholar
  16. 16.
    Livalo (pitavastatin) product information. Montgomery, AL: Kowa Pharmaceuticals America, Inc.; 2010.Google Scholar
  17. 17.
    Aoki T, Nishimura H, Nakagawa S, et al. Pharmacologic profile of a novel synthetic inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A reductase. Arzneim Forsch. 1997;47:904–909.Google Scholar
  18. 18.
    Acemoglu M, Brodbeck A, Garcia A, et al. A new and efficient synthesis of the HMG-CoA reductase inhibitor pitavastatin. Helv Chim Acta. 2007;90:1069–1081.CrossRefGoogle Scholar
  19. 19.
    Hayashi T, Yohote K, Saito Y, Iguchi A. Pitavastatin: efficacy and safety in intensive lipid lowering. Expert Opin Pharmacother. 2007;8;2315–2327.PubMedCrossRefGoogle Scholar
  20. 20.
    Morikawa S, Umetani M, Nakagawa S, et al. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells. J Atheroscler Thromb. 2000;7:138–144.PubMedGoogle Scholar
  21. 21.
    Suzuki H, Aoki T, Tamaki T, et al. Hypolipidemic effect of NK-104, a potent HMG-CoA reductase inhibitor, in guinea pigs. Atherosclerosis. 1999;146:259–270.PubMedCrossRefGoogle Scholar
  22. 22.
    Yanagita T, Hara E, Yotsumoto H, et al. NK-104 a potent new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, enhances posttranslational catabolism of apolipoprotein B-100 and inhibits secretion of apolipoprotein B-100 and triacylglycerols from HepG2 cells. Curr Therap Res. 1999;60:423–434.CrossRefGoogle Scholar
  23. 23.
    Yokoyama T, Miyauchi K, Kurata T, et al. Inhibitory efficacy of pitavastatin on the early inflammatory response and neointimal thickening in a porcine coronary after stenting. Atherosclerosis. 2004;174:253–259.PubMedCrossRefGoogle Scholar
  24. 24.
    Hiraoka M, Yoshida M. A novel HMG-CoA reductase inhibitor, pitavastatin inhibits IL-6-induced CRP in liver cells via ERK 1/2-dependent but not STAT3-dependent signaling transduction. Circ J. 2003;67(suppl. 1):271.Google Scholar
  25. 25.
    Hayashi T, Rani P, Fukatsu A, et al. A new HMG-CoA reductase inhibitor, pitavastatin remarkably retards the progression of high cholesterol induced atherosclerosis in rabbits. Atherosclerosis. 2004;176:255–263.PubMedCrossRefGoogle Scholar
  26. 26.
    Wang J, Tokoro T, Matsui K, et al. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-AKT pathway in endothelial cells. Life Sci. 2005;76:2257–2268.PubMedCrossRefGoogle Scholar
  27. 27.
    Maeda K, Yasunari K, Sato E, et al. Enhanced oxidative stress in neutrophils from hyperlipidemic guinea pig. Atherosclerosis. 2005;181:87–92.PubMedCrossRefGoogle Scholar
  28. 28.
    Kohno M, Shinomiya K, Abe S, et al. Inhibition of migration and proliferation of rat vascular smooth muscle cells by a new HMG-CoA reductase inhibitor, pitavastatin. Hypertens Res. 2002;25:279–285.PubMedCrossRefGoogle Scholar
  29. 29.
    Markle RA, Han J, Summers BD, et al. Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. J Cell Biochem. 2003;90:23–32.PubMedCrossRefGoogle Scholar
  30. 30.
    Masamura K, Oida K, Kanehara H, et al. Pitavastatin-induced thrombomodulin expression by endothelial cells acts via inhibition of small G proteins of the Rho family. Arterioscler Thromb Vasc Biol. 2003;23:512–517.PubMedCrossRefGoogle Scholar
  31. 31.
    Fujino H, Yamada I, Shimada S, et al. Metabolic fate of pitavastatin, a new inhibitor of HMG-CoA reductase: human UDP-glucuronosyltransferase enzymes involved in lactonization. Xenobiotica. 2003;33:27–41.PubMedCrossRefGoogle Scholar
  32. 32.
    Shimada S, Fujino H, Hojima J, et al. Uptake mechanism of pitavastatin, a new inhibitor of HMG-CoA reductase, in rat hepatocytes. Drug Metab Pharmacokinet. 2003;18:245–251.PubMedCrossRefGoogle Scholar
  33. 33.
    Hirano M, Maeda K, Shitara Y, et al. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther. 2004;311:139–146.PubMedCrossRefGoogle Scholar
  34. 34.
    Hasanuma T, Nakamura M, Yaji T, et al. The drug-drug interactions of pitavastatin (NK-104), a novel HMG-CoA reductase inhibitor and cyclosporine. J Clin Therap Med. 2003;19:381–389.Google Scholar
  35. 35.
    Lovastatin product information. Princeton, NJ: Sandoz Inc.; 2007.Google Scholar
  36. 36.
    Lipitor (atorvastatin) product information. New York, NY: Pfizer; 2009.Google Scholar
  37. 37.
    Crestor (rosuvastatin) product information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2010.Google Scholar
  38. 38.
    Simvastatin product information. Dayton, NJ: Aurobindo Pharma USA, Inc.; 2008.Google Scholar
  39. 39.
    Pravastatin product information. Sellersville, PA: Teva Pharmaceuticals USA; 2009.Google Scholar
  40. 40.
    Lescol (fluvastatin) product information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2006.Google Scholar
  41. 41.
    Hui CK, Cheung MY, Lau GKK, et al. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol. 2004;59:291–297.CrossRefGoogle Scholar
  42. 42.
    Kajinami K, Koizumi J, Ueda K, et al. Effects of NK-104, a new hydroxymethylglutarylcoenzyme reductase inhibitor, on low-density lipoprotein cholesterol in heterozygous familial hypercholesterolemia. Am J Cardiol. 2000;85:175–183.CrossRefGoogle Scholar
  43. 43.
    Noji Y, Higashikata T, Inazu A, et al. Long-term treatment with pitavastatin (NK-104), a new HMG-CoA reductase inhibitor, of patients with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:157–164.PubMedCrossRefGoogle Scholar
  44. 44.
    Saito Y, Yamada N, Teramoto T, et al. Clinical efficacy of pitavastatin, a new 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in patients with hyperlipidemia. Drug Res. 2002;52:251–255.Google Scholar
  45. 45.
    Koshiyama H, Taniguchi A, Tanaka K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) Investigators. J Atheroscler Thromb. 2008;15:345–350.PubMedCrossRefGoogle Scholar
  46. 46.
    Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus Pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;132:373–379.CrossRefGoogle Scholar
  47. 47.
    Park S, Kang HJ, Rim SJ, et al. A randomized, open-label study to evaluate the efficacy and safety of pitavastatin compared with simvastatin in Korean patients with hypercholesterolemia. Clin Ther. 2005;27:1074–1082.PubMedCrossRefGoogle Scholar
  48. 48.
    Yoshitomi Y, Ishii T, Kaneki M, et al. Efficacy of a low dose of pitavastatin compared with atorvastatin in primary hyperlipidemia: results of a 12-week, open label study. J Atheroscler Thromb. 2006;13:108–113.PubMedCrossRefGoogle Scholar
  49. 49.
    Lee SH, Chung N, Kwan J, et al. Comparison of the efficacy and tolerability of pitavastatin and atorvastatin: an 8-week, multicenter, randomized, open-label, dose-titration study in Korean patients with hypercholesterolemia. Clin Ther. 2007;29:2365–2373.PubMedCrossRefGoogle Scholar
  50. 50.
    Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients Collaborative study on Hypercholesterolemia drug Intervention and their Benefits for Atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008;201:345–335.PubMedCrossRefGoogle Scholar
  51. 51.
    Sasaki J, Ikeda Y, Kuribayashi T, et al. A 52-week, randomized, open-label, parallel-group comparison of the tolerability and effects of pitavastatin and atorvastatin on high-density lipoprotein cholesterol levels and glucose metabolism in Japanese patients with elevated levels of low-density lipoprotein cholesterol and glucose intolerance. Clin Ther. 2008;30:1089–1101.PubMedCrossRefGoogle Scholar
  52. 52.
    Budinski D, Arneson V, Hounslow N, et al. Pitavastatin compared with atorvastatin in primary hypercholesterolemia or combined dyslipidemia. Clin Lipidol. 2009;4:291–302.CrossRefGoogle Scholar
  53. 53.
    Sansanayudh N, Wongwiwatthananukit S, Putwai P, et al. Comparative efficacy and safety of low-dose pitavastatin versus atorvastatin in patients with hypercholesterolemia. Ann Pharmacother. 2010;44:507–514.CrossRefGoogle Scholar
  54. 54.
    Takashima H, Ozaki Y, Yasukawa T, et al. Impact of lipid-lowering therapy with pitavastatin, a new HMG-CoA reductase inhibitor, on regression of coronary atherosclerotic plaque: a 3-dimensional intravascular ultrasound study. Circ J. 2007;71:1678–1684.PubMedCrossRefGoogle Scholar
  55. 55.
    Nakamura T, Obata J, Kitta Y, et al. Rapid stabilization of vulnerable carotid plaque within 1 month of pitavastatin treatment in patients with acute coronary syndrome. J Cardiovasc Pharmacol. 2008;51:365–371.PubMedCrossRefGoogle Scholar
  56. 56.
    Toi T, Taguchi I, Yoneda S, et al. Early effect of lipid-lowering therapy with pitavastatin on regression of coronary atherosclerotic plaque: comparison with atorvastatin. Circ J. 2009;73:1466–1472.PubMedCrossRefGoogle Scholar
  57. 57.
    Miyauchi K, Kimura T, Morimoto T, et al. Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS): rationale and design. Circ J. 2006;70:1624–1628.PubMedCrossRefGoogle Scholar
  58. 58.
    Hiro T, Kimura T, Morimoto T, et al. Effect of intensive statin therapy on regression of coronary atherosclerosis in patients with acute coronary syndrome: a multicenter randomized trial evaluated by volumetric intravascular ultrasound using pitavastatin versus atorvastatin (JAPAN-ACS). J Am Coll Cardiol. 2009;54:293–302.PubMedCrossRefGoogle Scholar
  59. 59.
    Sone H, Takahashi A, Shimano H, et al. HMG-CoA reductase inhibitor decreases small dense low-density lipoprotein and remnant-like particle cholesterol in patients with type-2 diabetes. Life Sci. 2002;71:2403–2412.PubMedCrossRefGoogle Scholar
  60. 60.
    Motomura T, Okamoto M, Kitamura T, et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. J Atheroscler Thromb. 2009;16:546–552.PubMedCrossRefGoogle Scholar
  61. 61.
    Hiro T, Kimura T, Morimoto T, et al. Diabetes mellitus is a major negative determinant of coronary plaque regression during statin therapy in patients with acute coronary syndrome: serial intravascular ultrasound observations from the JAPAN-ACS trial. Circ J. 2010;72:1165–1172.CrossRefGoogle Scholar
  62. 62.
    Tokuno A, Hirano T, Hayashi T, et al. The effects of statin and fibrate on lowering small dense LDL-cholesterol in hyperlipidemic patients with type 2 diabetes. J Atheroscler Thromb. 2007;14:128–132.PubMedCrossRefGoogle Scholar
  63. 63.
    Nomura S, Inami N, Shouzu A, et al. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. Platelets. 2009;20:16–22.PubMedCrossRefGoogle Scholar
  64. 64.
    Kimura K, Shimano H, Yokote K, et al. Effects of pitavastatin (LIVALO Tablet) on the estimated glomerular filtration rate (eGFR) in hypercholesterolemic patients with chronic kidney disease: sub-analysis of the LIVALO Effectiveness and Safety (LIVES) study. J Atheroscler Thromb. 2010;17:601–609.PubMedCrossRefGoogle Scholar
  65. 65.
    Nakamura T, Sato E, Fujiwara N, et al. Co-administration of ezetimibe enhances proteinuria-lowering effects of pitavastatin in chronic kidney disease patients partly via a cholesterol-independent manner. Pharmacol Res. 2010;61:58–61.PubMedCrossRefGoogle Scholar
  66. 66.
    Ose L, Budinski D, Hounslow N, et al. Long-term treatment with pitavastatin is effective and well tolerated by patients with primary hypercholesterolemia or combined dyslipidemia. Atherosclerosis. 2010;210:202–208.PubMedCrossRefGoogle Scholar
  67. 67.
    Kobayashi M, Chisaki I, Narumi K, et al. Association between risk of myopathy and cholesterol-lowering effect: a comparison of all statins. Life Sciences. 2008;82:969–975.PubMedCrossRefGoogle Scholar
  68. 68.
    Baker WL, Talati R, White CM, et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010;87:98–107.PubMedCrossRefGoogle Scholar
  69. 69.
    Kawai T, Tokui M, Funae O, et al. Efficacy of pitavastatin, a new HMG-CoA reductase inhibitor, on lipid and glucose metabolism in patients with type 2 diabetes. Diabetes Care. 2005;28:2980–2981.PubMedCrossRefGoogle Scholar
  70. 70.
    Hirano M, Maeda K, Shitara Y, et al. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Disp. 2006;34:1229–1236.CrossRefGoogle Scholar
  71. 71.
    Choi CI, Bae JW, Moon SM, et al. Effects of clarithromycin on the pharmacokinetics of pitavastatin. Basic Clin Pharmacol Tox. 2009;105(suppl. 1):70. Abstract MP 104.Google Scholar
  72. 72.
    Fujino H, Yamada I, Shimada S, et al. Interaction between fibrates and statins: metabolic interactions with gemfibrozil. Drug Metab Drug Int. 2003;19:161–176.CrossRefGoogle Scholar
  73. 73.
    Fujino H, Saito T, Tsunenari Y, et al. Effect of gemfibrozil on the metabolism of pitavastatin: determining the best animal model for human CYP and UGT activities. Drug Metab Drug Int. 2004;20:25–42.CrossRefGoogle Scholar
  74. 74.
    Mathew P, Cuddy T, Tracewell WG, et al. An open-label study on the pharmacokinetics (PK) of pitavastatin (NK-104) when administered concomitantly with fenofibrate or gemfibrozil in healthy volunteers. Clin Pharmacol Ther. 2004;75:P33. Abstract PI-115.CrossRefGoogle Scholar
  75. 75.
    Ando H, Tsuruoka S, Yanagihara H, et al. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol. 2005;60:494–497.PubMedCrossRefGoogle Scholar
  76. 76.
    Mak WLV, Hu M, Yin Q, et al. Interaction of pitavastatin with grapefruit juice in subjects with different efflux transporter BRCP ABCG2 421C>A genotypes. Int J Cardiol. 2008;125(suppl. 1):S59. Abstract P 327.CrossRefGoogle Scholar

Copyright information

© Springer Healthcare 2010

Authors and Affiliations

  1. 1.Schools of Pharmacy and MedicineUniversity of ConnecticutStorrs and FarmingtonUSA

Personalised recommendations